This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Biologically-induced Animal Model Development Service
Introduction
Do you struggle to develop clinically relevant disease models or to manage complex preclinical studies? BioVenic's biologically-induced animal model development services offer advanced, ready-to-use models and efficient, non-GLP preclinical assay systems. We utilize diverse induction techniques-from tumor cell transplantation to advanced viral vector delivery-to simplify your R&D process and deliver high-quality scientific outcomes.
BioVenic Biologically-induced Animal Model Development Services
BioVenic Biologically-induced Animal Model Construction
BioVenic provides expertise in model development in all three aspects of biologically induced disease modeling:
Infection and Pathogen Challenge Models: BioVenic uses precise inoculations of relevant pathogens (bacteria, fungi, viruses, and parasites) to model acute and/or chronic infections and disease states. These models are used in antimicrobial and vaccine therapies. BioVenic knows how to choose the right animal strain to make it the right amount of susceptible to infection (for example, C57BL/6 for severe sepsis and BALB/c for immune response studies).
Oncology and Humanization Models through Transplantation: Employing intricate methodologies for the implantation of biological materials, including tumor cell line-derived xenografts (CDX), patient-derived xenografts (PDX), and the meticulous integration of human immune cells or tissues into immunodeficient animals to create humanized models.
Molecular and Biologic Induction Models: Creating models that use the targeted delivery of non-cellular biological agents, like recombinant toxins (for example, alpha-Hemolysin for cytotoxicity), molecular components (for example, Bleomycin for fibrosis), or advanced AAV viral vectors to make specific human disease genes (for example, SNCA for neurodegeneration) in target organs.
Biologically-induced Animal Model Validation and Characterization
BioVenic has developed a rigorous validation process to test each and every model developed against predefined pathological endpoints to ensure success prior to testing in the context of therapy:
Pathological Confirmation: Consists of a comprehensive histological evaluation (H&E, specific stains, IHC) and semi-quantitative pathological scoring (e.g., fibrosis score, inflammatory index) to determine the extent of damage.
Biomarker Quantification: Using extremely sensitive molecular and immunoassays (qPCR, ELISA), precise quantification of important biomarkers of disease development, such as pathogen load (CFU/titer), tumor dynamics (volume/metastases), cytokine expression, and soluble factors.
Phenotypic Analysis: Is the rapid, non-invasive assessment of disease progression using in vivo imaging and clinical grading systems (such as arthritis or neurological deterioration).
Downstream Preclinical Non-GLP Assay Services for Biologically-induced Animal Models
Building on the established models, the BioVenic team assists in the conduct of comprehensive non-GLP preclinical studies aimed at assessing drug efficacy and mechanism of action:
Efficacy and Pharmacodynamics (PD) Studies: Evaluation of novel pharmaceuticals on designated primary endpoints pertinent to the model (e.g., tumor mass reduction, fibrosis area decrease, enhancement of survival rate).
Mechanism of Action (MoA) Analysis: A thorough study of how a drug works on important pathways, such as immune cell analysis and targeting.
Biomaterial Sample Collection: Precise collection and processing of critical samples (blood, serum, target tissue, specific cell populations) for subsequent PK/PD or mechanistic analysis by the client or our team.
Explore BioVenic's investigative modalities:
- Animal Behavioral Analysis
- Animal Histopathology Service
- Preclinical Animal Pharmacodynamics (PD) Study
- Preclinical Animal Pharmacokinetics (PK) Study
- Animal Cell Biology Service
- Animal lmaging Service
We also provide other animal model development services, including:
- Genome-edited Animal Model Development
- Chemically-induced Animal Model Development
- Diet-induced Animal Model Development
- Surgically-induced Animal Model Development
Development Workflow for a Biologically-induced Animal Model
Common Biologically-induced Animal Models
BioVenic's biologically-induced animal models utilize various species (mice, rabbit, rat) and are essential for drug screening, vaccine evaluation, and mechanistic studies in oncology, infectious diseases, and autoimmune disorders.
Table. 1 Biologically-induced Animal Models
| Model Category | Model Construction Method (Inducing Agent) | Common Animal Species | Representative Model Examples | Primary Downstream Applications |
|---|---|---|---|---|
| I. Pathogen Inoculation (Infection) Models | Bacterial/Fungal Inoculation: Scratches/wounds on cornea/skin or intravenous injection of bacterial/fungal suspension. | Mice (C57BL/6, BALB/c), Rabbit, Pig | S. pneumoniae infection, S. aureus skin infection, C. albicans keratitis/sepsis models | Screening of anti-infective drugs (antibiotics, antifungals), efficacy assessment of novel vaccines and antibodies, study of bacterial/fungal virulence factors. |
| Viral Inoculation: putting a viral suspension into the nose or trachea; using strains that make animals more susceptible to infection. | Mice, Rabbit, Sheep, Cattle | Influenza virus infection, Respiratory Syncytial Virus infection, species-specific virus challenge models (e.g., feline, rabbit) | Preclinical screening of antiviral drugs, evaluation of vaccine immunogenicity and safety. | |
| Parasite Inoculation: involves injecting infective cysts under the skin or giving them orally, often along with immunosuppressants. | Mice, Rabbit | Trypanosome infection model | Validation of immune prevention strategies, screening of anti-parasitic drugs. | |
| AAV Vector Induction: Injection of SNCA wild-type or mutant AAV vector into specific tissues. | Mice, Rats | Parkinson's Disease (SNCA AAV), Alzheimer's Disease, ALS AAV models | Preclinical efficacy studies of gene therapy, investigation of disease pathogenesis, and novel therapeutic targets. | |
| II. Cell/Tissue Transplantation Models | Xenograft: Implantation of human tumor cell lines (CDX) or Patient-Derived Tumor Tissue (PDX) subcutaneously or orthotopically into immunodeficient mice. | Mice (NOD/SCID, Nude, Humanized) | Multi-cancer PDX models (lung, colorectal, breast, etc.), CDX models | Screening anti-cancer drugs activity, PDX-guided personalized therapy schemes, research into tumor metastasis and resistance mechanisms. |
| Humanized Models: The transplantation of human Peripheral Blood Mononuclear Cells (HuPBMCs) or Hematopoietic Stem Cells (HuHSC). | Immunodeficient Mice | Humanized Immune System models | Assessment of immunotherapy agents, study of human infectious diseases. | |
| Other Tissue Grafts: Transplantation of human skin, cornea, vascular valves, or gene-edited cells either under the skin or in their normal place. | Nude Mice, Nude Rats | Skin scar tissue transplantation model | Evaluation of anti-fibrotic drugs and gene therapy vectors, study of tissue regeneration and scarring. | |
| III. Biomolecule-Induced Models | Toxin/Enzyme Induction: Intratracheal instillation of Bleomycin; corneal injection of Alpha-Hemolysin or PASP; local injection of collagenase. | Mice, Rabbit, Rats | Bleomycin-induced pulmonary fibrosis model, Alpha-Hemolysin corneal injury model | Evaluation of anti-fibrotic drugs, anti-toxin antibodies, enzyme inhibitors efficacy, study of enzyme-mediated tissue destruction and remodeling. |
| Recombinant Biologic Induction: Injection of collagen, Freund's adjuvant, recombinant cytokines/hormones, etc. | Mice, Rabbit | Collagen-Induced Arthritis (CIA) model, EAE model (simulating Multiple Sclerosis) | Screening drugs for autoimmune diseases, study of physiological regulation mechanisms. |
Advantages of BioVenic Biologically-induced Animal Model Development Service
Diverse Model Host Portfolio:
BioVenic offers a wide range of specialized research hosts, including important immunodeficient strains like Nude Mice and SCID mice, which are necessary for tumor transplantation and building humanized models. We accommodate specific requirements for animal age, weight, and sex.
Scientifically Guided Customization:
Our process is hypothesis-driven. BioVenic combines your research goals, your existing data, and our extensive knowledge of model characteristics to create a customized study design that has the greatest chance of arriving at conclusive scientific answers.
Comprehensive Oncology Cell Line Resource:
BioVenic has created a large collection of well-characterized tumor cell lines and strong protocols for getting and storing PDX tissues. These are the biological materials that are needed to do a wide range of translational oncology studies.
Integrated One-Stop Service Platform:
BioVenic is in charge of the whole study process, from designing the model to validating it, testing it in vivo, and analyzing the final data. Our integrated service model, utilizing our internal capabilities and external partners, eliminates the need to manage multiple vendors and ensures efficient study delivery.
Case Study: Synergistic Anti-Tumor Evaluation in a Squamous Cell Lung Cancer Xenograft Model
Our oncology platform provides standardized biologically induced subcutaneous xenograft models utilizing human lung squamous cell carcinoma lines and other tumor cell lines in BALB/c nude mice. We ensure rigorous validation of modeling success and therapeutic efficacy through longitudinal caliper measurements for precise Tumor Growth Inhibition (TGI) calculations, coupled with high-resolution H&E histopathology to quantify the central necrosis characteristics. Furthermore, our advanced IHC services for targets such as CD31 and Ki-67 provide quantitative insights into microvascular density and cellular proliferation. As a premier oncology CRO, we provide highly reproducible modeling, integrated precision micro-irradiation, and comprehensive tumor microenvironment analysis to streamline and accelerate your development of next-generation synergistic anti-cancer regimens.
Fig.1 Evaluation of the Anti-tumor Efficacy1
FAQs
How do you make sure that your biological models are useful for translation?
We use a validation process that is based on measurable things like how quickly tumors grow, how bad the disease is (for example, fibrosis grade), or how many pathogens are present. This makes sure that the response can predict the state of the person.
When the project is finished, what kind of information will I receive?
A comprehensive final report comprising the experimental design, data, statistical analysis, and a scientific assessment of the drug's efficacy, including its relationship to analytical and in vivo data (such as survival and tumor growth), will be provided to you. (e.g., AAV expression, biomarkers).
Can you conduct studies on larger animals such as rabbits?
Indeed. For larger animal models, such as those with greater surface area requirements (like collagen-induced arthritis) or those with particular anatomical considerations for ocular, cutaneous, or respiratory infections, we employ rabbits and rats.
Contact Us
BioVenic's knowledge of Biologically Induced Animal Model Development, which includes precise pathogen challenge, advanced tumor transplantation, and AAV gene delivery, is what makes preclinical research successful. If your drug development program requires robust non-GLP models and excellent in vivo data, we provide the specialized solutions and scientific expertise you require. To discuss your unique project requirements and obtain a thorough consultation, get in touch with us right now.
References
- Kim, Min-Young, et al. "Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma." BMC cancer 20.1 (2020): 1057. https://doi.org/10.1186/s12885-020-07566-x. Distributed under Open Access license CC BY 4.0. The original title was changed to "Evaluation of the Anti-tumor Efficacy".